Fig. 1 · Structure

Documents & Downloads

GS-9620

Cat. No. A13251 CAS 1228585-88-3

TLR7 agonist

GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7.

In Stock

Publications for GS-9620

2 publications citing this product

  1. Yu-Geun Ji, .et al. , J Pharm Biomed Anal, 2019, 12 November, 112987 PMID: 31761376
  2. Zhikuan Zhang, .et al. , Cell Reports, 2018, 25(12): 3371-3381.e5 PMID: 30566863

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

GS-9620 activates human TLR7-dependent signaling. In a Huh7 reporter model, substitutions at Y356, F408, D555 and L557 markedly reduced its response. Retained IL-1β signaling and detectable mutant-receptor expression supported a receptor-associated effect. The proposed binding interactions derive from modeling and functional mutagenesis rather than a direct binding-affinity measurement. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
TLR7

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 EC50 290 nM Agonist activity at human TLR7 expressed in HEK293 cells by reporter based assay [PMID: 23961878]
HEK293 EC50 9 μM Agonist activity at human TLR8 expressed in HEK293 cells by reporter based assay [PMID: 23961878]

GS-9620 Research Summary

This section summarizes 2 in vitro studies of GS-9620 from 1 published reference.

GS-9620 In Vitro Studies

In healthy-donor PBMCs exposed to 1 μM GS-9620, pDCs showed increased NF-κB p65 S529 and Akt S473 phosphorylation over 5–60 minutes. The respective readouts peaked at 30 and 60 minutes within that interval. Responses were stronger in pDCs than in donor-matched mDCs. These cell-signaling observations do not establish antiviral efficacy or a clinical dose. [1]

Structure-guided TLR7 reporter response and validation controls

Cell-based study · Huh7 cells expressing wild-type or mutant human TLR7 with an NF-κB luciferase reporter; empty-vector control. [1]

GS-9620 activated the wild-type TLR7 reporter. Y356S, F408A, D555A, L557D and L557Y/T586G variants had strongly reduced GS-9620 responses. The L557 variants retained more resiquimod responsiveness, whereas Y356S, F408A and D555A impaired both agonists. Control substitutions outside the proposed pocket retained activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
GS-9620-induced NF-κB reporter response in Y356S, F408A, D555A, L557D and L557Y/T586G TLR7 variants versus wild-type TLR7Reporter AUC reduction 4-fold or greater reduction[1]
Resiquimod response and reporter/expression controlsComparative response Y356S, F408A and D555A also showed 4-fold or greater AUC reduction with resiquimod; IL-1β reporter responses and TLR7 protein expression were retained across tested constructs.[1]

Literature-Reported Treatment Conditions

Treatment concentration
GS-9620: four-point two-fold titration starting at 5 μM; resiquimod: starting at 10 μM.
Exposure duration
Compounds added 24 h after transfection; luciferase measured after 20 h stimulation.
Method
Cell-based NF-κB luciferase reporter assay.
Vehicle
DMSO vehicle and normalization control; final percentage not specified in the cited reporter methods.
Co-treatment
Agonists tested separately; IL-1β used as a separate signaling control.
Reported limits
No binding affinity or receptor-occupancy measurement; no EC50 fitted for this study. Salt state and analytical purity not established in selected sections.
Methods and source locations

Compound reported in the paper: GS-9620; Compound label in the paper: GS-9620; resiquimod comparator

Evidence concerns the authors’ GS-9620 material; it does not validate an Adooq lot or establish equivalence of formulations.

Fig 2b–c and caption; Results: structure-guided mutational analysis; NF-κB reporter assay methods; S4a–c and caption

GS-9620-induced NF-κB reporter response in Y356S, F408A, D555A, L557D and L557Y/T586G TLR7 variants versus wild-type TLR7: Luciferase normalized to DMSO; four-point two-fold compound titration. Caption reports mean and SEM of triplicate assay conditions; representative of three independent experiments. — Fig 2b–c and caption; Results: structure-guided mutational analysis; NF-κB reporter assay methods; S4a–c and caption

Resiquimod response and reporter/expression controls: Resiquimod reporter comparator; IL-1β bypass control in S4b; anti-TLR7 immunoblot with GAPDH control in S4c. No densitometric equality is inferred. — Fig 2b–c and caption; Results: structure-guided mutational analysis; NF-κB reporter assay methods; S4a–c and caption

Early NF-κB and Akt signaling in primary human dendritic-cell subsets

Cell-based study · Healthy-donor PBMCs; gated plasmacytoid dendritic cells (pDCs) and donor-matched myeloid dendritic cells (mDCs). [1]

At 1 μM, GS-9620 increased phosphorylation readouts in pDCs, with NF-κB p65 S529 peaking at 30 min and Akt S473 at 60 min within the tested 5–60 min interval. Responses were stronger in pDCs than in donor-matched mDCs; mDC readouts showed little change. These are short-term signaling endpoints, not antiviral efficacy measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
pDC NF-κB p65 S529 phosphorylation relative to DMSOTime of peak within sampled interval 30 min[1]
pDC Akt S473 phosphorylation relative to DMSO; dendritic-subset comparisonTime of peak within sampled interval 60 min[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM GS-9620 in Fig 5; 1 μM resiquimod comparator in Fig 5c.
Exposure duration
5, 10, 15, 30 and 60 min time course; Fig 5a illustrates NF-κB at 30 min and Akt at 60 min.
Method
PBMC stimulation followed by fixation, phospho-specific staining and flow cytometry within dendritic-cell gates.
Vehicle
DMSO comparator; final percentage not specified in the cited phospho-flow methods.
Co-treatment
GS-9620 and resiquimod tested separately.
Reported limits
Absolute MFI values and raw donor-level data were not retrieved; no exact fold changes estimated from plots. A peak at the final sampled time is not an established later maximum.
Methods and source locations

Compound reported in the paper: GS-9620; Compound label in the paper: GS-9620; resiquimod comparator

Evidence concerns the authors’ GS-9620 material; it does not validate an Adooq lot or establish equivalence of formulations.

Fig 5a–c and caption; Results: GS-9620 activates NF-κB and Akt pathways; Phospho-flow cytometry and Statistical Analysis methods; S7a gating

pDC NF-κB p65 S529 phosphorylation relative to DMSO: Phospho-flow cytometry; DMSO-normalized MFI. Fig 5 caption: 6 independent donors, mean ± SEM; p<0.05 versus DMSO at all assessed time points. Statistics section specifies two-tailed unpaired t-test. — Fig 5a–c and caption; Results: GS-9620 activates NF-κB and Akt pathways; Phospho-flow cytometry and Statistical Analysis methods; S7a gating

pDC Akt S473 phosphorylation relative to DMSO; dendritic-subset comparison: Phospho-flow cytometry; DMSO-normalized MFI. Fig 5 caption: 4 independent donors, mean ± SEM; p<0.05 versus DMSO at 10, 15, 30 and 60 min. Fig 5c reports stronger responses in pDCs than matched mDCs, p<0.01 for both phospho-readouts with either agonist. — Fig 5a–c and caption; Results: GS-9620 activates NF-κB and Akt pathways; Phospho-flow cytometry and Statistical Analysis methods; S7a gating

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 1228585-88-3
Applications TLR7 agonist
Formula C22H30N6O2
Molecular Weight 410.51
SMILES
CCCCOC1=NC2=C(C(=N1)N)NC(=O)CN2CC3=CC(=CC=C3)CN4CCCC4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 1 mg/mL (2.43 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

GS-9620 Research References

  1. [1] Indrani Rebbapragada, Gabriel Birkus, Jason Perry, et al. Molecular Determinants of GS-9620-Dependent TLR7 Activation PLOS ONE (2016). PMID: 26784926 DOI: 10.1371/journal.pone.0146835 Source material

Publications

2 publications citing this product

  1. Yu-Geun Ji, .et al. , J Pharm Biomed Anal, 2019, 12 November, 112987 PMID: 31761376
  2. Zhikuan Zhang, .et al. , Cell Reports, 2018, 25(12): 3371-3381.e5 PMID: 30566863

Added to your cart

View Cart Checkout
Loading...